NKE vs NKTR · P/E 35, rev $46.40B vs rev $21.0M
Nike Inc (NKE) versus Nektar Therapeutics (NKTR) — a side-by-side from cached financials, not a winner call.
Nike Inc (NKE) is a footwear & accessories company listed on US. It is led by Elliott J. Hill.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Latest reported NKE revenue for 2026-05-31 was $46.40B. Net income was $3.11B. NKE currently screens at market cap $110.14B and trailing P/E 34.6.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
NKE currently screens at market cap $110.14B and trailing P/E 34.6. NKTR currently screens at market cap $307.2M.
Not investment advice. Open the NKE and NKTR stock pages for the full models.
Not investment advice.